Shots:

• Novavax has identified a coronavirus vaccine candidate- NVX-CoV2373 utilizing its nanoparticle technology and will initiate a first-in-human trial in mid-May with its anticipated immunogenicity and safety results in July. Novavax will integrate its Matrix-M adjuvant with NVX-CoV2373 to improve the immune response stimulates high levels of neutralizing Ab
• The company plans to combine P-I/II study- allowing the rapid advancement during a pandemic. The P-I clinical study will assess NVX-CoV2373 vs PBO in ~130 healthy adults and includes an assessment of dosage amount and the number of vaccinations
• Earlier- the company collaborated with Emergent BioSolutions to provide GMP vaccine products for use in its clinical trials. Additionally- the CEPI has granted $4M to support Novavax’ efforts- with additional funding discussions ongoing

Click here ­to­ read full press release/ article | Ref: Novavax | Image: Glassdoor